1.
Scolnick EM. The Path to New Therapies for Schizophrenia and Bipolar Illness. FASEB J. 2017;31(4):1254-1259. doi:10.1096/fj.201700028.
1.
Marder SR, Roth B, Sullivan PF, et al. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011;1236:30-43. doi:10.1111/j.1749-6632.2011.06216.x.
1.
Perlis RH, Smoller JW, Ferreira MAR, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009;166(6):718-25. doi:10.1176/appi.ajp.2009.08111633.
1.
Weïwer M, Xu Q, Gale JP, et al. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment. ACS Chem Biol. 2018;13(4):1038-1047. doi:10.1021/acschembio.8b00168.
1.
Zelikowsky M, Hui M, Karigo T, et al. The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress. Cell. 2018;173(5):1265-1279.e19. doi:10.1016/j.cell.2018.03.037.
1.
Scolnick EM. Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations. Biol Psychiatry. 2006;59(11):1039-45. doi:10.1016/j.biopsych.2006.02.022.
1.
Scolnick E. Program to improve cognitive functioning in patients with schizophrenia: reflections. Schizophr Res. 2004;72(1):75-7. doi:10.1016/j.schres.2004.09.005.
1.
Hyman SE. Target practice: HDAC inhibitors for schizophrenia. Nat Neurosci. 2012;15(9):1180-1. doi:10.1038/nn.3200.
1.
Hyman SE. Time for new schizophrenia Rx. Science. 2014;343(6176):1177. doi:10.1126/science.1252603.
1.
Goldstein JI, Jarskog F, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757. doi:10.1038/ncomms5757.